title: NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.
abstract: We studied the clinical role of leukocyte infiltration and chemokine receptor expression in ovarian carcinoma effusions. Expression of leukocyte markers (CD3, CD4, CD8, CD4/CD8 ratio, CD16, CD19, and CD14) and chemokine receptors (CXCR1, CXCR4, CCR2, CCR5, and CCR7) was studied in 73 effusions by using flow cytometry. CXCR4, CCR5, and CCR7 were expressed abundantly on leukocytes, but all receptors were expressed rarely on cancer cells. The presence of natural killer cells (P = .042) and International Federation of Gynecology and Obstetrics (FIGO) stage IV disease (P = .024) predicted worse overall survival (OS). A higher percentage of CD19+ cells (P = .015) and stage IV disease (P = .008) predicted poor survival for patients with postchemotherapy effusions. Only FIGO stage retained significance as a predictor of OS (P = .035) in multivariate analysis. Chemokine receptors are expressed widely on leukocytes but rarely on carcinoma cells in ovarian carcinoma effusions, arguing against an autocrine chemokine pathway in this malignancy. Immune response parameters in ovarian cancer effusions are weak predictors of outcome.
authors.affiliation: Department of Pathology, Norwegian Radium Hospital, University of Oslo, Norway.
authors.forename: Hiep Phuc
authors.initials: HP
authors.lastname: Dong
authors.forename: Mari Bunkholt
authors.initials: MB
authors.lastname: Elstrand
authors.forename: Arild
authors.initials: A
authors.lastname: Holth
authors.forename: Ilvars
authors.initials: I
authors.lastname: Silins
authors.forename: Aasmund
authors.initials: A
authors.lastname: Berner
authors.forename: Claes G
authors.initials: CG
authors.lastname: Trope
authors.forename: Ben
authors.initials: B
authors.lastname: Davidson
authors.forename: Björn
authors.initials: B
authors.lastname: Risberg
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000556:secondary*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001202:Ascitic Fluid / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D014408:Biomarkers, Tumor / Q000378:metabolism; D002634:Chemotaxis, Leukocyte / Q000276:immunology; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D010996:Pleural Effusion / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D019707:Receptors, Chemokine / Q000378:metabolism; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D019707:Receptors, Chemokine